Clinical Trial Update: An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Intetumumab (CNTO 95) in metastatic castration-resistant prostate cancer has completed and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Intetumumab (intetumumab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-05-20